Cannabidiol Inhibits COVID Replication

The spread of SARS-CoV-2 and ongoing COVID-19 pandemic underscores the need for new treatments. Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription.

Cannabidiol inhibits COVID

CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α RNase endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against use of non-medical formulations including edibles, inhalants or topicals as a preventative or treatment therapy at the present time.

Our results suggest that CBD and its metabolite 7-OH-CBD can block SARS-CoV-2 infection at early and even later stages of infection. The mechanism appears to be mediated in part by activation of the IRE1α RNase and interferon pathways. In addition to these cell-based findings, pre-clinical studies show that CBD treatment reduced viral titers in the lungs and nasal turbinates of SARS-CoV-2-infected mice. Finally, analysis of a national sample of patients with active records of 100 mg/ml CBD consumption at the time of COVID testing revealed an association with substantially fewer SARS-CoV-2 positive test results. This negative association was robust to many sensitivity analyses, including changes in the matching and outcomes models, and merits further research into the potential of CBD to combat SARS-CoV-2 infection, such as validation in other large, multi-site electronic health record datasets or prospective experimental designs.

Read full article from Science Advances

Cannabinoids May Prevent Infection with SARS-CoV-2, Including Variants

A new study published in the Journal of Natural Products of the American Chemical Society and American Society of Pharmacognosy has shown that isolated cannabinoids or those in hemp extracts have the potential to prevent and treat the infection with the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) – primarily by blocking viral cell entry.

SARS-CoV-2 image

One of the primary worries in the ongoing coronavirus disease 2019 (COVID-19) pandemic is the spread of many different viral variants known for successfully evading antibodies against early SARS-CoV-2 lineage. An additional concern is that currently implemented vaccination strategies rely on the receptor-binding domain (RBD) of spike glycoprotein from an initially identified SARS-CoV-2 strain.

As a strategy complemental to vaccines, small-molecule treatment agents are necessary in order to treat or prevent infections by SARS-CoV-2 and its variant. This is where we can again turn to natural products as one of the most successful sources of drugs and drug leads in the history of pharmacology.

For example, it is already known that hemp (Cannabis sativa L.) is used for food, animal feed, and fiber; furthermore, various hemp extracts and compounds have become well-accepted additions to food and dietary supplements, as well as cosmetics and body lotions.

However, is there also a role for cannabinoids as one of the potential treatment solutions during the current pandemic? This research question was recently tackled by a team of scientists led by Dr. Richard B. van Breemen from the Linus Pauling Institute at Oregon State University in the United States.

Source: News Medial Life Sciences

Zev Speaks About Identifying Quality Hemp Seeds

Zev Paiss, COO at Abraham Paiss and Associates, spoke about hemp seeds as part of his presentation in a recent webinar hosted by the National Center for Appropriate Technology (NCAT). West Coast Hemp Webinar : Regulation, Compliance, and Insurance, on November 4. It was a huge success! Feel free to share, if you’d like.

hemp seeds

Finding hemp seeds that perform as advertised can be challenging. Given the lack of stable genetics, identifying seeds that perform well in a specific geographical region and interviewing seed breeders are all ways to reduce the risk of purchasing seeds that do not germinate as expected or generate more makes than the farmer can deal with are hurdles hemp farmers face.


Choosing a safe and trusted CBD partner source is one of the most important elements, if not the most important, in kick-starting your business. Finding a credible CBD supplier allows you to confidently share the details about your CBD sourcing with consumers and will help ensure the product you are creating is consistent.

Following passage of the 2018 farm bill that legitimized hemp farming and processing, there has been an increase in hemp CBD product manufacturing in the United States. More CBD products are available for those seeking benefits, but an abundance of quantity can lead to a loss of quality. As we continue to grow as an industry, how can we make sure our CBD is free of harmful additives and safe for consumers?

Read full article …

The Hemp Access and Consumer Safety Act

We are thrilled to report the introduction today of The Hemp Access and Consumer Safety Act  which would establish a legal and regulatory pathway for the sale of hemp-derived extract products such as CBD as dietary supplements and food and beverage additives.  We especially applaud Senator Ron Wyden (D-OR), a longtime and enduring hemp supporter, for drafting this bill which will help stabilize hemp markets, open a promising economic opportunity for U.S. farmers, and protect consumers by requiring hemp extract product manufacturers to comply with the entire existing comprehensive regulatory framework for ingestible products.  We are also grateful to Senators Rand Paul (R-KY) and Jeff Merkley (D-OR) for serving as original co-sponsors of this much needed, bi-partisan legislation. Contact your Senators here!


LONGMONT, Colo. – May 4, 2021 – High Grade Hemp Seed, a Santa Fe Farms company and a leader in the production and sales of premium hemp genetics, has received AOSCA certification of its top-performing CBG varietal, Matterhorn CBG.

The Association of Official Seed Certifying Agencies (AOSCA) is dedicated to the production, identification, distribution and promotion of certified classes of seed. Its certification of Matterhorn CBG paves the way for High Grade and its trusted affiliates to distribute to States, Countries and Native American Nations where certification of seed is required for entry into their ag markets as well as other markets where certification is unnecessary.

Wrangler Parent Expands Hemp Collaboration With Panda Biotech

Kontoor Brands Inc., with a brand portfolio led by Lee and Wrangler, announced an expansion of its collaboration with Dallas-based Panda Biotech, an emerging leader in the industrial hemp fiber industry, on Tuesday.

Kontoor Brands and Panda Biotech will work to bring traceability and scale to the textile-grade cottonized hemp grown and processed in the United States. Read more …

Can Hemp Grain & Fiber Acreage Eclipse CBDs’ This Year?

The magnitude of oversupply in the CBD market this year could reduce the amount of hemp acreage dedicated to cannabinoid production by more than 70% from 2020. Though total U.S. licensed hemp acreage in 2020 declined by 30% from its peak in 2019, it still produced more material than the industry could process and sell: Much more.

Such is the extent of the glut of biomass in the market that many extractors are still using material from 2019 crops to make their products. Consumer demand for CBD products is still growing, and quickly, but the requisite amount of acreage necessary to feed that demand is drastically smaller than what was grown in 2020. Read more …